New guidelines for recognising and managing concussion in grassroots sports have been published by the Government. Aimed at the general public and those engaging with sport on a non-professional level, ‘If In Doubt, Sit Them Out’ is guidance with a very clear message that if an individual is suspected of having concussion, they must be…
Eisai submits a marketing authorisation application (MAA) for lecanemab
Eisai has submitted a Marketing Authorisation Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in the brain,1 to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. This…
Parliamentary ABI reception attracts hundreds of attendees
UKABIF trustees and members attended an Acquired Brain Injury reception in Parliament hosted by Chris Bryant MP. Around 60 MPs from across the House attended to hear first hand from people living with an acquired brain injury, just what improvements need to be made. It was a wonderful opportunity for organisations to network and for…
THN391 – First in-human dosing in phase 1 trial in Alzheimer’s disease
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease THN391 binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in neurodegenerative and ophthalmologic diseases. Based on preclinical studies to date, targeting this region does not impact or diminish fibrin’s critical…
Acute migraine treatment accepted for use on NHS in Scotland
9th May, 2023: Pfizer Ltd announced that the Scottish Medicines Consortium (SMC) has accepted Vydura ® (rimegepant) for restricted use for the treatment of acute migraine with or without aura, for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and…
Karger Publishers Launches its Fourth Annual Vesalius Innovation Award to Advance the Future of Science
For the fourth consecutive year, Karger Publishers is seeking top-of-the-line applicants for its Vesalius Innovation Award. The award is aimed at early-stage startups in the Health Sciences and Publishing sectors that are developing innovative technological solutions with a significant impact in their respective fields. This year marks the fourth year of the Vesalius Innovation Award,…
FDA approves QALSODY™ (tofersen) targeting a genetic cause of ALS
25 April 2023: Ionis Pharmaceuticals, Inc today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval…
Gene in the brain can reduce anxiety in animal model
A gene in the brain driving anxiety symptoms has been identified by an international team of scientists. Modification of the gene is shown to reduce anxiety levels, offering a novel drug target for anxiety disorders. The discovery, led by researchers at the Universities of Bristol and Exeter, was published online online on 25th April in Nature…
#AAN2023: Atogepant for preventive treatment of episodic migraine
21 April 2023: AbbVie has announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications. The results of the study demonstrated adult patients in the atogepant 60 mg once daily (QD) arm experienced…
